GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sareum Holdings PLC (LSE:SAR) » Definitions » Total Payout Ratio

Sareum Holdings (LSE:SAR) Total Payout Ratio : 0.95 (As of Dec. 15, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Sareum Holdings Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Sareum Holdings's current Total Payout Ratio is 0.95.


Sareum Holdings Total Payout Ratio Historical Data

The historical data trend for Sareum Holdings's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sareum Holdings Total Payout Ratio Chart

Sareum Holdings Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.51 1.45 1.44 - 0.95

Sareum Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.54 1.96

Competitive Comparison of Sareum Holdings's Total Payout Ratio

For the Biotechnology subindustry, Sareum Holdings's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sareum Holdings's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sareum Holdings's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Sareum Holdings's Total Payout Ratio falls into.



Sareum Holdings Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Sareum Holdings's Total Payout Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 4.375 + 0) / -4.602
=0.95

Sareum Holdings's Total Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 2.598 + 0) / -1.328
=1.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sareum Holdings Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Sareum Holdings's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sareum Holdings Business Description

Traded in Other Exchanges
N/A
Address
Langford Arch, London Road, Unit 2a, Pampisford, Cambridge, Cambridgeshire, GBR, CB22 3FX
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.